https://www.biopharmawatch.com/news/ROIV/roivant-phase-2-phocus-study-results-ers-congress-2026 BiopharmaWatch en 2026-09-06T05:00:00.000Z Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call https://www.biopharmawatch.com/news/SYK/stryker-participate-2026-wells-fargo-healthcare-conference BiopharmaWatch en 2026-09-04T22:32:00.000Z Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/GH/guardant-health-fda-approval-guardant360-cdx BiopharmaWatch en 2026-09-04T22:10:00.000Z Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer https://www.biopharmawatch.com/news/DTC/defence-therapeutics-sharing-agreement-update BiopharmaWatch en 2026-09-04T22:00:00.000Z Defence Therapeutics Provides Updates on Sharing Agreement https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-04T21:05:00.000Z Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/IONS/pelacarsen-phase-3-results-lpahorizon BiopharmaWatch en 2026-09-04T20:41:00.000Z Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) https://www.biopharmawatch.com/news/NVS/novartis-lpa-horizon-phase-iii-results-pelacarsen BiopharmaWatch en 2026-09-04T20:30:00.000Z Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-investor-conferences-2026 BiopharmaWatch en 2026-09-04T20:05:00.000Z Rapid Micro Biosystems to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/NMAD/nomad-power-solutions-special-meeting-adjournment BiopharmaWatch en 2026-09-04T20:05:00.000Z NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS https://www.biopharmawatch.com/news/APMD/apnimed-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-09-04T20:01:00.000Z Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-wells-fargo-conference-2026 BiopharmaWatch en 2026-09-04T20:01:00.000Z Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/INBX/inhibrx-webcast-inbrx-106-phase-2-results BiopharmaWatch en 2026-09-04T20:00:00.000Z Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study